Kansas legislators were scheduled on March 10 to consider a bill supported by Bayer that would bar plaintiffs from suing pesticide manufacturers for failing to warn that their products could cause cancer or other illnesses. The measure arrives as Bayer prepares a proposed settlement exceeding $7 billion to resolve thousands of claims tied to the weedkiller Roundup.
The Kansas proposal is part of a broader push by Bayer: roughly a dozen bills the company has backed in statehouses around the country. The company has also pursued action at the federal level designed to reduce the risk of future litigation connected to glyphosate-based pesticides.
Earlier this month Bayer unveiled a proposed $7.25 billion agreement intended to settle the bulk of nearly 65,000 outstanding lawsuits alleging Roundup caused cancer. Bayer acquired Roundup when it completed a $63 billion purchase of the agrochemical company Monsanto in 2018, inheriting a large volume of litigation from people who say the product caused them to develop cancer.
A company spokesperson said Bayer is supporting both state and federal legislative measures to try to limit further Roundup-related suits. The legislative strategy has produced mixed results so far: two Bayer-backed bills have passed in North Dakota and Georgia, while the fate of the Kansas bill remains unclear.
Opposition to the Kansas measure centers on skepticism about the U.S. Environmental Protection Agency's finding that glyphosate pesticides such as Roundup are not likely to cause cancer. Supporters of the bill, meanwhile, express concern that legal restrictions or liability risks could lead manufacturers to raise prices or remove glyphosate products from the market, a result they say would harm businesses in a state with significant agricultural activity.
State lawmakers described an intense flow of constituent correspondence on the issue. Democratic state senator Silas Miller, who serves on the agriculture committee, said he was receiving large volumes of emails in favor of and opposed to the bill and had not made a decision about how to vote. Republican committee member Kenny Titus said he had been inundated with messages on both sides and planned to oppose the measure.
Financial strain from the litigation has already shown up in Bayer's accounts. During an earnings call on March 4 the company reported a fourth-quarter net loss of about 3.76 billion euros, attributing part of that loss to legal costs tied to Roundup litigation.
Beyond state legislatures, Bayer is also a defendant in a Supreme Court case scheduled for argument in April that will address whether the company had a duty to warn customers that glyphosate could cause cancer. In parallel federal action, the House Agriculture Committee advanced a draft farm bill that would require uniform pesticide labels nationwide. If enacted as written, the bill would prevent local governments from mandating health warnings on pesticide labels that differ from language used by the EPA - a measure Bayer supports.
In February, an executive order from the U.S. President encouraged expanded domestic production of glyphosate-based herbicides like Roundup. That directive prompted criticism from a group referred to in public commentary as the MAHA coalition. Some activists aligned with that coalition, which includes individuals who supported the President in 2024 and who now hold roles in the administration, reacted negatively to the move.
Kelly Ryerson, a pesticide activist associated with the MAHA coalition, criticized the executive order on social media, noting that it sought to expand production of what the post described as a carcinogenic pesticide. The article referenced that Robert F. Kennedy Jr. is serving as Health and Human Services Secretary and is among administration figures connected to the MAHA-aligned constituency.
Kenny Titus said that overlap between his priorities and positions held by the MAHA movement had created divisions among conservatives, complicating GOP lawmaker responses to pesticide-related measures.
Separately, a Missouri state court judge has given preliminary approval to Bayer's proposed $7.25 billion settlement in a nationwide class-action brought by people who claim Roundup caused them to develop non-Hodgkin lymphoma. The judge said he will hear objections from those affected before making a final determination in July about whether to grant definitive approval.
Exchange rate referenced in prior reporting: 1 euro = $1.17.
Key points
- Bayer is backing a Kansas bill that would limit lawsuits over pesticide warnings, part of about a dozen state-level measures the company supports.
- The company has proposed a $7.25 billion settlement intended to resolve most of roughly 65,000 Roundup lawsuits it inherited when it acquired Monsanto in 2018.
- Bayer faces parallel legal and legislative challenges - a Supreme Court case on duty-to-warn claims and a federal push for uniform pesticide labeling that could preempt local warning requirements.
Sectors impacted - Agriculture, agrochemicals, legal services, and broader corporate litigation exposure in the chemicals sector.
Risks and uncertainties
- Legislative uncertainty - The Kansas bill's outcome was not certain; state-level measures have seen mixed success, with only North Dakota and Georgia having passed bills so far. This injects uncertainty for agricultural businesses and manufacturers operating in affected states.
- Judicial outcomes - Bayer remains engaged in litigation at the Supreme Court and in state courts; the Supreme Court hearing in April and the Missouri judge's decision on final settlement approval in July present potential swings in liability exposure and legal precedent.
- Market and policy responses - Federal actions such as the draft farm bill and the presidential executive order to expand domestic glyphosate production have provoked public and political backlash, creating potential regulatory and reputational risks for companies tied to glyphosate-based products.
Note: Reporting is based on the facts made available about legislative, judicial, and corporate actions and statements. Where details were not specified, this piece reflects only the information that was provided.